Adocia SA (ADOCP.XC)
| Previous close | 7.82 |
| Open | 7.82 |
| Bid | 8.13 x N/A |
| Ask | 8.27 x N/A |
| Day's range | 7.82 - 7.82 |
| 52-week range | 3.35 - 10.16 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 144.778M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions
LYON, France, June 18, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, is pleased to announce that exclusive data from three of Adocia’s innovative technology platforms have been selected for poster presentations at the upcoming American Diabetes Association’s (ADA) 84th Scientific Sessions to be held J
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of May 31st, 2024
LYON, France, June 17, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions fo
- Business Wire
ADOCIA Confirms Its Eligibility for the PEA–PME
LYON, France, June 06, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, confirms its eligibility for the "PEA – PME" stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014.
